Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $69,650.76 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 95,412 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $0.73, for a total value of $69,650.76. Following the transaction, the director directly owned 2,010,508 shares in the company, valued at $1,467,670.84. The trade was a 4.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $39,025.71.
• On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.85, for a total value of $45,849.00.

Werewolf Therapeutics Price Performance

NASDAQ HOWL opened at $0.72 on Friday. The business’s fifty day moving average price is $0.81 and its 200-day moving average price is $0.89. The stock has a market capitalization of $35.14 million, a price-to-earnings ratio of -0.53 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 1-year low of $0.53 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.14. Equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on HOWL shares. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Hold” and an average price target of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in Werewolf Therapeutics by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after buying an additional 221,766 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Bank of America Corp DE grew its position in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the second quarter valued at about $409,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.